Top > Search of International Patents > PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF CANCER

PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF CANCER

Foreign code F180009655
File No. 3995
Posted date Nov 21, 2018
Country WIPO
International application number 2014JP054893
International publication number WO 2014133085
Date of international filing Feb 27, 2014
Date of international publication Sep 4, 2014
Priority data
  • P2013-037426 (Feb 27, 2013) JP
Title PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF CANCER
Abstract Abacavir, which is a nucleoside analogue reverse transcriptase inhibitor, has been found to exhibit anti-cancer activity with respect to ATL cells in vitro, without hindering the DNA replication of normal cells. Abacavir, or a pharmacologically acceptable derivative thereof, is effective as an active ingredient of pharmaceutical compositions for the prevention and/or treatment of cancer, and in particular breast cancer and cancers having abnormalities in the DNA repair mechanism, such as adult T-cell leukemia.
Outline of related art and contending technology BACKGROUND ART
Nucleoside reverse transcriptase inhibitors (NRTI: Nucleoside Analogue Reverse Transcriptase Inhibitor) is, anti-human immunodeficiency virus type 1 (hereinafter 'HIV-1' hereinafter) has been developed as a drug, an anti-HIV treatment current nuclei are used as a medicament. However, with respect to zidovudine (AZT) from its prototype, as well as the reverse transcription of the virus, can also induce DNA replication of normal cells has been known (see non-patent document 1). On the other hand, the same human retrovirus HIV-1 human T-cell leukemia virus type 1 (hereinafter 'HTLV-1' hereinafter) with respect to, various types of nucleic acid-based reverse transcriptase inhibitor antiviral effect in or to be known. Further, due to the infection HTLV-1 (Adult T cell Leukemia adult T-cell leukemia, hereinafter referred to as' ATL ') in the treatment of combination therapy with zidovudine and interferon (IFN) is performed, then the effect is reported (non-patent document 2, reference 3). However, in the in vitro anti-cancer effect to the cell that ATL zidovudine is reported that it is not (see non-patent document 4) and, the mechanism of action of zidovudine ATL cells that is unknown in many cases.
Which is a kind of NRTI abacavir (ABC) is in clinical use as an anti-HIV and, also has an effect of anti-HTLV-1 have been reported (see non-patent document 5). However, anti-cancer effect of abacavir has not been known.
Scope of claims (In Japanese)請求の範囲 [請求項1]
 アバカビルまたはその製薬上許容される誘導体を有効成分として含有するがんの予防または治療用医薬組成物。

[請求項2]
 DNA修復機構に異常を有するがんの予防または治療用である請求項1に記載の医薬組成物。

[請求項3]
 DNA修復機構に異常を有するがんが、TDP1の発現量が低下しているがんである請求項2に記載の医薬組成物。

[請求項4]
 肺がんまたはヒトT細胞白血病ウイルス1型感染に起因するがんの予防または治療用である請求項1~3のいずれかに記載の医薬組成物。

[請求項5]
 成人T細胞白血病の予防または治療用である請求項1~4のいずれかに記載の医薬組成物。

[請求項6]
 PARP阻害剤と組み合わせて使用される請求項1~5のいずれかに記載の医薬組成物。

[請求項7]
 トポイソメラーゼ阻害剤と組み合わせて使用される請求項1~5のいずれかに記載の医薬組成物。

[請求項8]
 DNA切断作用を有する請求項1~7のいずれかに記載の医薬組成物。

[請求項9]
 細胞周期停止作用および/またはアポトーシス誘発作用を有する請求項1~7のいずれかに記載の医薬組成物。

[請求項10]
 アバカビルまたはその製薬上許容される誘導体を有効成分として含有するHTLV-1感染に起因する疾患の予防または治療用医薬組成物。

  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • KYOTO UNIVERSITY
  • Inventor
  • TAKAORI, Akifumi
  • TAKEDA, Shunichi
  • KOBAYASHI, Masayuki
  • TADA, Kohei
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN TD TG
Please contact us by e-mail or facsimile if you have any interests on this patent. Thanks.

PAGE TOP

close
close
close
close
close
close